Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Bar

Showing results (531-540 of 540) with videos related to

Pageof 54
Sort By:
You have reached the last page of results.This site can display upto 540 results.
The New England Journal of Medicine|August 4, 2021
Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19Meagan P O'Brien, Eduardo Forleo-Neto, Bret J Musser, et al.
Medrxiv : the Preprint Server for Health Sciences|June 23, 2021
Subcutaneous REGEN-COV Antibody Combination for Covid-19 PreventionMeagan P O'Brien, Eduardo Forleo-Neto, Bret J Musser, et al.
JAMA|January 14, 2022
Effect of Subcutaneous Casirivimab and Imdevimab Antibody Combination vs Placebo on Development of Symptomatic COVID-19 in Early Asymptomatic SARS-CoV-2 Infection: A Randomized Clinical TrialMeagan P O'Brien, Eduardo Forleo-Neto, Neena Sarkar, et al.
Medrxiv : the Preprint Server for Health Sciences|June 23, 2021
Subcutaneous REGEN-COV Antibody Combination in Early Asymptomatic SARS-CoV-2 Infection: A Randomized Clinical TrialMeagan P O'Brien, Eduardo Forleo-Neto, Neena Sarkar, et al.
The Journal of Clinical Investigation|November 17, 2021
A randomized controlled study of convalescent plasma for individuals hospitalized with COVID-19 pneumoniaKatharine J Bar, Pamela A Shaw, Grace H Choi, et al.
The New England Journal of Medicine|December 14, 2016
Effect of HIV Antibody VRC01 on Viral Rebound after Treatment InterruptionKatharine J Bar, Michael C Sneller, Linda J Harrison, et al.
Science Immunology|February 13, 2026
Env-antibody coevolution identifies B cell priming as the principal bottleneck to HIV V2 apex broadly neutralizing antibody developmentRumi Habib, Ryan S Roark, Hui Li, et al.
Biorxiv : the Preprint Server for Biology|June 12, 2025
Env-antibody coevolution identifies B cell priming as the principal bottleneck to HIV-1 V2 apex broadly neutralizing antibody developmentRumi Habib, Ryan S Roark, Hui Li, et al.
ESMO Open|January 24, 2026
Global advances and future directions in lung cancer care: expert consensus and strategic prioritiesM-L Meyer, S Peters, P A Jänne, et al.
Science (New York, N.Y.)|November 20, 2020
Recapitulation of HIV-1 Env-antibody coevolution in macaques leading to neutralization breadthRyan S Roark, Hui Li, Wilton B Williams, et al.
Pageof 54

Showing results (531-540 of 540) with videos related to

Sort By:
Pageof 54
You have reached the last page of results.This site can display upto 540 results.
The New England Journal of Medicine|August 4, 2021
Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19Meagan P O'Brien, Eduardo Forleo-Neto, Bret J Musser, et al.
Medrxiv : the Preprint Server for Health Sciences|June 23, 2021
Subcutaneous REGEN-COV Antibody Combination for Covid-19 PreventionMeagan P O'Brien, Eduardo Forleo-Neto, Bret J Musser, et al.
JAMA|January 14, 2022
Effect of Subcutaneous Casirivimab and Imdevimab Antibody Combination vs Placebo on Development of Symptomatic COVID-19 in Early Asymptomatic SARS-CoV-2 Infection: A Randomized Clinical TrialMeagan P O'Brien, Eduardo Forleo-Neto, Neena Sarkar, et al.
Medrxiv : the Preprint Server for Health Sciences|June 23, 2021
Subcutaneous REGEN-COV Antibody Combination in Early Asymptomatic SARS-CoV-2 Infection: A Randomized Clinical TrialMeagan P O'Brien, Eduardo Forleo-Neto, Neena Sarkar, et al.
The Journal of Clinical Investigation|November 17, 2021
A randomized controlled study of convalescent plasma for individuals hospitalized with COVID-19 pneumoniaKatharine J Bar, Pamela A Shaw, Grace H Choi, et al.
The New England Journal of Medicine|December 14, 2016
Effect of HIV Antibody VRC01 on Viral Rebound after Treatment InterruptionKatharine J Bar, Michael C Sneller, Linda J Harrison, et al.
Science Immunology|February 13, 2026
Env-antibody coevolution identifies B cell priming as the principal bottleneck to HIV V2 apex broadly neutralizing antibody developmentRumi Habib, Ryan S Roark, Hui Li, et al.
Biorxiv : the Preprint Server for Biology|June 12, 2025
Env-antibody coevolution identifies B cell priming as the principal bottleneck to HIV-1 V2 apex broadly neutralizing antibody developmentRumi Habib, Ryan S Roark, Hui Li, et al.
ESMO Open|January 24, 2026
Global advances and future directions in lung cancer care: expert consensus and strategic prioritiesM-L Meyer, S Peters, P A Jänne, et al.
Science (New York, N.Y.)|November 20, 2020
Recapitulation of HIV-1 Env-antibody coevolution in macaques leading to neutralization breadthRyan S Roark, Hui Li, Wilton B Williams, et al.
Pageof 54